Running for a reason
In 2021 at 34 years old, Couch was told she had stage three cervical cancer.
'It was very scary, I was in a little room and the doctor came in and seven residents came in and I was like, this is not a good sign.'
At the time, the doctors were worried it may be stage four cancer, which is a terminal diagnosis.
Luckily for Couch it hadn't spread that far and she is now in remission
Sara began running after she finished treatment.
'It was just recommended as a good way to help reduce occurrence and mortality risks to get your strength back, your immune system.'
On Monday she will run in the Boston Marathon as part of the Dana-Farber team. After her initial diagnosis, Sara received a second opinion from the cancer institute in Boston.
Dana-Farber also funded an immuno-therapy drug that was helpful to Couch as well.
'Every time I run I just feel such immense gratitude to even have the ability to be that healthy because when I finished treatment I was in a wheelchair. I started walking five minutes, then I would walk ten minutes.'
Being able to combine something she's so appreciative for, with now being able to help others is very personal for Sara.
'I was gifted so much, right, I was gifted family that helped, an employer that helped, amazing amazing medical care from a lot of doctors and a lot of institutions that came together and that's why I'm here.' Couch said. 'And it took everyone, so if I can give back just a little bit to someone else to have that chance with their daughter, that's what I want to do.'
From barely being able to walk for five minutes, Couch is now gearing up to run 26 miles.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CBS News
4 days ago
- CBS News
Boston Children's nurse completes virtual Pan-Mass Challenge after missing race for stem cell donation
A Boston Children's Hospital nurse wasn't expecting to be in a hospital bed when she was meant to be riding in the Pan-Mass Challenge, but she was grateful it was for a life-changing reason: stem cell donation. Kristin McIntire is no stranger to long rides. The Boston nurse has completed 10 marathons and several 100-mile bike races. "I love exercise. I love being active," she said, jokingly adding that she commutes to work on her bike. "I don't know if you're familiar with Boston traffic, but it's certainly the most easy way to get around." But for McIntire, riding has always been about more than just fitness. It's personal and it's purposeful. "I've always needed to align that with a higher purpose, that I don't feel like I'm doing it by myself. So whether that's riding with a team, running with a team fundraising for a group, it's been a lot more meaningful for me," McIntire said. For years, McIntire served as a pediatric oncology nurse at Boston Children's Hospital, working on one of the most intense and emotional floors in the building. "There are other outcomes that aren't so great... where the family is leaving without their child," she recalled. "And that's really, really sad." She rides in the Pan-Mass Challenge with Pedal for Pediatrics, a team made up of coworkers that raises money for children and families facing cancer at Dana-Farber and Boston Children's. But last year, just as she was preparing for the big ride, Kristin received a life-changing message: she'd been matched as a stem cell donor. "It was honestly so crazy. I was like, wait, what?" McIntire said. She spent what would've been Pan-Mass Challenge weekend in a hospital bed in Florida, donating stem cells to a stranger with leukemia. "That was a pretty cool reason to stop training, I would say," McIntire said. Though she couldn't be on the course, McIntire found another way to finish the journey. In the weeks after her donation, she completed multiple 50-mile rides virtually. "This team directly provides funding that benefits those patients directly, whether that's ride share services or meal coupons, anything that can help support this family," McIntire said. McIntire has never met the person she helped. She doesn't even know their name. But she knows they're still alive. "I saved a person's life, and I was a little tired after the donation, and that was it," McIntire said. "Whether you're riding, whether you're volunteering, or whether you're out there cheering— all of that matters, and it's very important work," she added. McIntire's stem cell procedure was not a traditional bone marrow surgery. Most donations today are done through a simple outpatient blood draw called peripheral blood stem cell donation. You can learn more or join the registry here.
Business Wire
6 days ago
- Business Wire
Azafaros Announces Initiation of two Global Phase 3 studies with Nizubaglustat in Niemann-Pick disease Type C (NPC) and GM1/GM2 gangliosidoses, respectively
LEIDEN, Netherlands--(BUSINESS WIRE)-- Azafaros, a company focused on developing treatments for the unmet needs of patients with rare lysosomal storage disorders, today announced that the first patient has been dosed in the company's pivotal, multicenter Phase 3 clinical program to evaluate the safety and efficacy of the company's lead asset, nizubaglustat, in patients with Niemann-Pick disease Type C (NPC) and GM1/GM2 gangliosidoses. 'The dosing of the first patient in our Phase 3 program with nizubaglustat is a significant achievement for Azafaros, and a huge step forward in our efforts to bring new, disease modifying treatments to patients with these seriously debilitating diseases,' Share The initiation of the two Phase 3 studies (NCT07054515) represents a major milestone in Azafaros' commitment to addressing the urgent unmet medical needs of children affected by these devastating neurodegenerative disorders. The Phase 3 program consists of two studies targeting the late-infantile and juvenile-onset forms of NPC, and GM1/GM2 gangliosidoses. The studies aim to assess the potential of nizubaglustat to alter disease progression and improve functional outcomes in these patient populations. Today's news follows the recent, successful completion of an oversubscribed series B financing, raising €132M to support the acceleration of nizubaglustat and the expansion of the company's pipeline to other indications. 'The dosing of the first patient in our Phase 3 program with nizubaglustat is a significant achievement for Azafaros and a huge step forward in our efforts to bring new, disease modifying treatments to patients with these seriously debilitating diseases,' said Stefano Portolano, Chief Executive Officer at Azafaros. 'We are deeply grateful to the patients, families, clinicians, and advocacy groups who are partnering with us to advance this promising therapy.' About the NAVIGATE trial The two 18-month randomized 2 to 1, double-blind, placebo-controlled trials will recruit patients at approximately 35 sites across 15 countries worldwide, including in the US, Europe and Latin America. The studies are expected to enroll around 70 patients. The primary endpoint for both trials is the change from baseline to Month 18 in the Scale for the Assessment and Rating of Ataxia (SARA), with both total and functional SARA scores evaluated. For more information on the Phase 3 program, please visit To enquire about trial participation, email: medinfo@ (if a professional) or patientadvocacy@ (if a patient or caregiver). To protect privacy, avoid including identifying information in the initial message. About nizubaglustat Nizubaglustat is a small molecule, orally available and brain penetrant azasugar with a unique dual mode of action, developed as a potential treatment for rare lysosomal storage disorders with neurological involvement, including GM1 and GM2 gangliosidoses and Niemann-Pick disease type C (NPC). Nizubaglustat has received Rare Pediatric Disease Designations (RPDD) for the treatment of GM1 and GM2 gangliosidoses and NPC, Orphan Drug Designations (ODD) for GM1 and GM2 gangliosidosis (Sandhoff and Tay-Sachs Diseases) and NPC, as well as Fast Track Designation and IND clearance for GM1/GM2 gangliosidoses and NPC from the US Food and Drug Administration (FDA). Additionally, nizubaglustat has been awarded Orphan Medicinal Product Designation (OMPD) for the treatment of GM1 and GM2 gangliosidoses by the European Medicines Agency (EMA) and Innovation Passport for the treatment of GM1 and GM2 gangliosidoses from the UK Medicines and Healthcare Products Regulatory Agency (MHRA). About GM1 and GM2 gangliosidoses GM1 gangliosidosis and GM2 gangliosidosis (Tay-Sachs and Sandhoff diseases) are lysosomal storage disorders caused by the accumulation of GM1 or GM2 gangliosides respectively, in the central nervous system (CNS). This results in progressive and severe neurological impairment and premature death. These diseases mostly affect infants and children, and no disease-modifying treatments are currently available. About Niemann-Pick disease Type C (NPC) Niemann-Pick disease Type C is a progressive, life-limiting, neurological, lysosomal storage disorder, caused by mutations in the NPC1 or NPC2 gene and aberrant endosomal-lysosomal trafficking, leading to the accumulation of various lipids, including gangliosides in the CNS. The onset of disease can happen throughout the lifespan of an affected individual, from prenatal life through adulthood. About Azafaros Azafaros is a clinical-stage company founded in 2018 with a deep understanding of rare genetic disease mechanisms using compound discoveries made by scientists at Leiden University and Amsterdam UMC and is led by a team of highly experienced industry experts. Azafaros aims to build a pipeline of disease-modifying therapeutics to offer new treatment options to patients and their families. By applying its knowledge, network and courage, the Azafaros team challenges traditional development pathways to rapidly bring new drugs to the rare disease patients who need them. Azafaros is supported by leading healthcare investors including Forbion, Jeito Capital, Seroba, Pictet Group, BioGeneration Ventures (BGV), BioMedPartners, Asahi Kasei Pharma Ventures, and Schroders Capital.
Time Business News
25-07-2025
- Time Business News
Breakthrough Innovations Transforming Lung Cancer Diagnosis and Treatment
Lung cancer is a type of cancer that begins in the lungs, often caused by smoking, exposure to pollutants, genetic factors or commercial threats. Lung cancer market is increasing due to growing global lung cancer rate, awareness and increase in screening programs, progress in clinical technologies (such as low -dosage CT scans and liquid biopsy) and increasing remedies and development of targeted remedies and immunotherapy. Additionally, better healthcare in aging population and emerging areas is promoting infrastructure and early detection and demand for effective treatment solutions. Key Growth Drivers and Opportunities Growing Global Lung Cancer Rate: Rising global lung cancer rate is a major driver of lung cancer market development, as it increases the demand for early identity, accurate diagnosis and effective treatment solutions. One of the major causes of cancer-related deaths worldwide with lung cancer, healthcare systems are making heavy investments in advanced screening tools such as low-dosage CT scans and biomarker-based diagnosis to enable the first diagnosis. At the same time, rising patient numbers are accelerating the development and adoption of innovative remedies including targeted drugs and immunotherapy. The burden of growing disease also attracts more research funds and industry investment, further fuel to market expansion. Challenges The lung cancer market faces several borders, including advanced diagnosis and high cost of targeted treatments, which can limit access to areas with especially low and moderate income. Delayed diagnosis also disrupts the results of treatment due to lack of awareness, limited screening programs and non-specific initial symptoms. Additionally, the challenge of complex regulatory routes, delayed stage patients, and the challenge of managing side effects from therapy disrupts the market growth despite technological progress. Innovation and Expansion EQUAL Study Launches High-Risk Group Lung Cancer Screening Trial In May 2025, Researchers at the Dana-Farber Cancer Institute have begun testing a new, in-house blood test in an effort to screen for lung cancer and identify those who are at a higher risk of developing the disease even if they have never used tobacco. Epidermal growth factor receptor (EGFR) gene mutations can be common in the Asian and Hispanic/Latinx populations, which is the subject of the EQUAL (EGFR ctDNA Quantitative Assessment for Lung Cancer screening in Asian and Latinx populations) study. Possessing this mutation increases the risk of lung cancer because EGFR type mutations are linked to the illness. Additionally, the number of cancer diagnoses among Asian or Hispanic/Latinx individuals is increasing at a faster rate. With India's First LungLife Screening Program to Fight Lung Cancer, Apollo Cancer Centre Sets the Standard In March 2025, India's first LungLife Screening Program for early lung cancer diagnosis has been introduced by Apollo Cancer Centres (ACCs), a pioneer in state-of-the-art cancer care. Lung cancer, which makes up 5.9% of all malignancies and 8.1% of cancer-related deaths in India, is the target of this ground-breaking project. Early identification increases the survival rate and improves treatment results (LINK). Low-dose computed tomography (LDCT) early screening can greatly increase survival chances and help with early diagnosis. However, almost 80% of high-risk patients have never spoken to their doctors about screening. To allow early detection and save lives, it is imperative to improve knowledge and communication regarding lung cancer screening, particularly among high-risk individuals. Inventive Sparks, Expanding Markets The key players operating the lung cancer market include AstraZeneca, Hoffman La Roche, Eli Lilly and Company, Pfizer Inc., Merck & Co., Amgen Inc., Novartis AG, Johnson & Johnson, Teva Pharmaceuticals Industries Ltd., Bristol-Myers Squibb Company. About Author: Prophecy is a specialized market research, analytics, marketing and business strategy, and solutions company that offer strategic and tactical support to clients for making well-informed business decisions and to identify and achieve high value opportunities in the target business area. Also, we help our client to address business challenges and provide best possible solutions to overcome them and transform their business. TIME BUSINESS NEWS
